Status:
COMPLETED
Assessment of What Patients and Healthcare Providers Value
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Gastric Adenocarcinoma
Pancreatic Adenocarcinoma
Eligibility:
All Genders
18+ years
Brief Summary
To assess the importance patients place on each of the attributes of value (i.e., outcomes, quality of life \[QOL\], cost, experience), and how these patients’ views differ depending on the stage of...
Detailed Description
PRIMARY OBJECTIVE: I. To assess the importance patients place on each of the attributes of value (i.e., outcomes, quality of life \[QOL\], cost, experience). SECONDARY OBJECTIVES: I. To assess whic...
Eligibility Criteria
Inclusion
- Any patient who has been treated, or is anticipated to be treated, for potentially resectable, biopsy-proven pancreatic adenocarcinoma, pancreatic neuroendocrine malignancy, or gastric adenocarcinoma
- Providers involved in the care of gastric and pancreatic cancer patients. Providers will include non-collaborative surgical oncologists, medical oncologists, radiation oncologists, administrators, nurses, mid-level providers
- Able to understand the description of the study and willing to participate
Exclusion
- Inability to read and answer questions in English
Key Trial Info
Start Date :
June 11 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 11 2022
Estimated Enrollment :
397 Patients enrolled
Trial Details
Trial ID
NCT04483349
Start Date
June 11 2020
End Date
August 11 2022
Last Update
August 31 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
M D Anderson Cancer Center
Houston, Texas, United States, 77030